Boston-based Atea Pharmaceuticals has raised $215m in a Series D financing round. The investment was led by Bain Capital Life Sciences; other new investors that participated in the round include Omega Funds, Rock Springs Capital and Redmile Group.
Some of Atea’s existing investors also participated, including Ally Bridge Group and Morningside Ventures. This funding will primarily be used to support Atea’s efforts against Covid-19.
The company recently received clearance from the US Food and Drug Administration (FDA) to advance its novel antiviral drug AT-527 into a Phase II clinical trial.
This study will evaluate the safety, tolerability and efficacy of AT-527 in those aged between 45 to 80 with moderate Covid-19 and risk factors for poor